Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 9/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.33 |
| ▸ | CSF1R | P07333 | 4/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30891513 | 1.00 | TGFBR1 (0.43) | TGFBR1AAK1PDGFRBPDGFRACSF1R | |
| SCHEMBL31740642 | 0.93 | TGFBR1 (0.42) | TGFBR1AAK1PDGFRBPDGFRACSF1R | |
| SCHEMBL31740432 | 0.93 | TGFBR1 (0.42) | TGFBR1AAK1PDGFRBPDGFRACSF1R | |
| SCHEMBL3947048 | 0.85 | TGFBR1 (0.53) | TGFBR1PDGFRBPDGFRACSF1RS1PR4 | |
| SCHEMBL31740748 | 0.84 | TGFBR1 (0.43) | TGFBR1AAK1PDGFRBPDGFRACSF1R | |
| SCHEMBL16028424 | 0.82 | SCN9A (0.43) | TGFBR1SCN5ASCN9A | |
| SCHEMBL22165803 | 0.80 | TGFBR1 (0.39) | TGFBR1PDGFRBPDGFRACSF1RS1PR4 | |
| SCHEMBL21425598 | 0.80 | TGFBR1 (0.39) | TGFBR1PDGFRBPDGFRACSF1R | |
| SCHEMBL3943494 | 0.79 | S1PR4 (0.48) | TGFBR1PDGFRBPDGFRASCN5ASCN9A | |
| SCHEMBL16059863 | 0.79 | TGFBR1 (0.43) | TGFBR1PDGFRBPDGFRACSF1RFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617775-B2 | Processes of making CSF-1R inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-05-05 | — | — | US | disclosed |
| US-12582655-B2 | Methods of treating disorders using CSFIR inhibitors | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260078107-A1 | CSF-1R INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260034131-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2026-02-05 | — | — | US | disclosed |
| US-12509443-B2 | CSF-1R inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250368622-A1 | PROCESSES OF MAKING CSF-1R INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250368621-A1 | CSF-1R INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12485120-B2 | Methods of treating disorders using CSF1R inhibitors | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4647767-A2 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4303583-B1 | CSF1R INHIBITORS FOR USE IN TREATING TENOSYNOVIAL GIANT CELL TUMORS | DECIPHERA PHARMACEUTICALS LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145028-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145023-A1 | 1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145015-A2 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145025-A2 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145025-A2 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145023-A1 | 1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | KIT, CSF1R, CSF3R | TGFBR1 1678/4885AAK1 596/4885PDGFRB 6/4885 |
| US-20260034131-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | CSF1R, CSF3R, ARG1 | TGFBR1 89/4885AAK1 4636/4885PDGFRB 132/4885 |
| US-12509443-B2 | CSF-1R inhibitors and methods of use thereof | CSF1R, CSF3R, FLT3 | TGFBR1 137/4885AAK1 552/4885PDGFRB 91/4885 |
| US-12617775-B2 | Processes of making CSF-1R inhibitors and methods of use thereof | CSF1R, CSF3R, FLT3 | TGFBR1 111/4885AAK1 991/4885PDGFRB 27/4885 |
| US-20250368621-A1 | CSF-1R INHIBITORS AND METHODS OF USE THEREOF | CSF1R, CSF3R, CMKLR1 | TGFBR1 511/4885AAK1 1790/4885PDGFRB 81/4885 |
| US-12485120-B2 | Methods of treating disorders using CSF1R inhibitors | CSF1R, CSF3R, CD68 | TGFBR1 365/4885AAK1 2860/4885PDGFRB 168/4885 |
| US-20260078107-A1 | CSF-1R INHIBITORS AND METHODS OF USE THEREOF | CSF1R, CSF3R, FLT3 | TGFBR1 124/4885AAK1 1252/4885PDGFRB 100/4885 |
| US-12582655-B2 | Methods of treating disorders using CSFIR inhibitors | CSF1R, CSF3R, MSR1 | TGFBR1 63/4885AAK1 4737/4885PDGFRB 92/4885 |
| US-20250368622-A1 | PROCESSES OF MAKING CSF-1R INHIBITORS AND METHODS OF USE THEREOF | CSF3R, CSF1R, FLT3 | TGFBR1 1516/4885AAK1 3691/4885PDGFRB 29/4885 |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | TGFBR1 1569/4885AAK1 406/4885PDGFRB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.